Cabozantinib Plus Atezolizumab for Non-Clear Cell Renal Cell Carcinoma

Cabozantinib Plus Atezolizumab for Non-Clear Cell Renal Cell Carcinoma

Kidney Cancer Conference Highlights from ASCO 2023Подробнее

Kidney Cancer Conference Highlights from ASCO 2023

CONTACT-303: primary PFS analysis of atezolizumab and cabozantinib in ccRCCПодробнее

CONTACT-303: primary PFS analysis of atezolizumab and cabozantinib in ccRCC

Nivolumab Plus Cabozantinib for Patients With Non-Clear Cell Renal Cell CarcinomaПодробнее

Nivolumab Plus Cabozantinib for Patients With Non-Clear Cell Renal Cell Carcinoma

Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell CarcinomaПодробнее

Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell Carcinoma

Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCCПодробнее

Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCC

Cab + atezo: a new treatment for naïve advanced ccRCCПодробнее

Cab + atezo: a new treatment for naïve advanced ccRCC

Dr. Choueiri on Atezolizumab Plus Bevacizumab in Non–Clear Cell RCCПодробнее

Dr. Choueiri on Atezolizumab Plus Bevacizumab in Non–Clear Cell RCC

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC